Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E; IMvigor130 Study Group. Galsky MD, et al. Among authors: park sh. Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0. Lancet. 2020. PMID: 32416780 Clinical Trial.
Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.
Kim K, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK. Kim K, et al. Among authors: park sh, park jo, park ch, park k. Am J Clin Oncol. 2002 Aug;25(4):354-7. doi: 10.1097/00000421-200208000-00007. Am J Clin Oncol. 2002. PMID: 12151964 Clinical Trial.
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Lee J, et al. Among authors: park kw, park ys, park jo, park sh, park k. Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90. doi: 10.1007/s00280-004-0837-7. Epub 2004 Jul 10. Cancer Chemother Pharmacol. 2004. PMID: 15248028 Clinical Trial.
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K. Park SH, et al. Among authors: park jo, park ch, park k, park j. Am J Clin Oncol. 2004 Oct;27(5):477-80. doi: 10.1097/01.coc.0000136018.81814.79. Am J Clin Oncol. 2004. PMID: 15596914 Clinical Trial.
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Lee J, et al. Among authors: park ys, park jo, park sh. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169686 Clinical Trial.
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS. Kim ST, et al. Among authors: park ys, park sh, park jo. Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1. Med Oncol. 2010. PMID: 19949897
10,746 results
You have reached the last available page of results. Please see the User Guide for more information.